The company also hopes to launch an early feasibility study in the United States in the near future. 

As more and more Americans receive their COVID-19 vaccine, heart failure patients and heart transplant recipients may have specific questions about how they should proceed.

The study’s authors tracked data from more than 2,800 patients with HFrEF, sharing their findings in JAMA Cardiology.

The guidance, an update to a similar document from 2005, was published in Circulation: Cardiovascular Quality and Outcomes.

Tracking a patient's longitudinal strain and circumferential strain may improve the ability to predict their risk of heart failure later in life. 

After tracking data for nearly 800 professional athletes, the researchers found that no adverse cardiac events were reported after a mild or asymptomatic COVID-19 infection.

This is a Class I recall, which means using the device can lead to serious injury or death.

“Medical providers should educate patients who may be at risk for severe COVID-19 and consider promoting preventive lifestyle measures,” one researcher said. 

This latest analysis is an extension of the COAPT trial, which had examined the safety and effectiveness of TMVR with the MitraClip device after two years.

Current heart failure definitions are "ambiguous and lack standardization," the groups wrote.